Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Political pressure and persistently high interest rates have some wondering if the industry’s model is broken.

Analysts defend the long-term profitability of health-oriented companies, traditionally defensive values that have now been ...

Cangelosi could choose, in front of Gemello, a three-man defense with Amoran, Riccardi and Dell'Orco, while on the left flanks he could have a Giraudo shirt (returning from suspension), while on the ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. On Thursday, April 3rd, the host of ...

European Union leaders are planning to travel to Beijing for a summit with Chinese President Xi Jinping in July, the South ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Shoppers browse a Walmart Supercenter a day after U.S. President Donald Trump announced new tariffs, in Secaucus, New Jersey, U.S. April 3, 2025. REUTERS/Siddharth Cavale/File photo U.S. consumer ...